Comparison of imipenem and ceftazidime as therapy for severe melioidosis

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Melioidosis, a severe bacterial infection, requires effective antibiotic treatment.
• High-dose intravenous antibiotics are crucial for managing acute, severe cases.

Purpose of the Study:

• To compare the efficacy of high-dose intravenous imipenem versus ceftazidime in treating acute severe melioidosis.
• To evaluate mortality and treatment failure rates between the two antibiotic regimens.

Main Methods:

• An open, prospective, randomized comparative trial.
• Adult Thai patients with suspected acute severe melioidosis received either imipenem (50 mg/kg/day) or ceftazidime (120 mg/kg/day) for at least 10 days.
• Outcomes assessed included death and treatment failure.

Main Results:

• Of 296 enrolled patients, 214 had culture-confirmed melioidosis.
• Overall mortality was 36.9%; no significant difference in survival was observed between imipenem and ceftazidime groups.
• Treatment failure after 48 hours was significantly more common in the ceftazidime group (P = .011).

Conclusions:

• High-dose imipenem is a safe and effective treatment for acute severe melioidosis.
• Imipenem demonstrates a potential advantage over ceftazidime due to lower treatment failure rates.
• Imipenem can be considered an alternative therapeutic option for severe melioidosis.